A polypill is a pill that contains multiple pharmaceutical ingredients. The idea is that for common conditions, like cardiovascular (heart) disease, a very cheap one-size-fits-all pill would actually bring great health benefits. Many people in rich countries do not bother to take multiple pills and in poor countries most people cannot afford them, or cannot afford to visit the doctor more than once.
In the case
of heart disease, it was shown that such a pill would cost about 10 cents and
would be highly effective and extend people's live by several years. Perhaps the
Penny Pill might be another name for it.
The main
problem with autism is that 90+% of doctors are not even trying to treat it and
are unaware of even the limited knowledge that does exist, to diagnose and treat
sub-types (eg Landau-Kleffner syndrome).
So it would
be clever to develop a one-size-fits-all pill and even if one or two of the
ingredients were ineffective in a particular patient, overall there would be a
big benefit. I was then thinking what I
would put in the Peter Polypill.
The Theoharides Polypill(s)
I was
pleasantly surprised to find that somebody else has had the same idea and has
gone so far as to patent it. Dr
Theoharides, from Tufts University in the US, has filed patents on several such
polypills. I have read much of his autism
and mast cell research and was beginning to wonder why, after 25 years in the
field, he has only brought to market an OTC supplement (Neuroprotek).
Just take a
look at what he would put in his autism polypill:-
and more
recently a very similar one:-
If you are a
doctor or science graduate, you will probably read the full patent information,
but if not, here is a summary:-
SUMMARY OF THE INVENTION
(Methods of treating autism spectrum disorders and compositions
for same)
[0007] It has been discovered that measurement of certain
serum markers capable of making brain blood vessels leaky can identify patients
with ASDs. It has also been discovered that certain compositions can inhibit
leakage of brain vessels that would otherwise allow entry of noxious molecules
in the brain. The compositions disclosed herein have been found to improve the
conditions associated with ASDs through inhibition of blood vessel leakage, as
determined by behavioral improvement and as noted in the examples disclosed
herein. Together, these data support that modulation, and, in particular,
inhibition, of brain blood vessel leakage is a valuable intervention point for
the treatment of ASDs. This discovery has been exploited to develop the present
application, which includes methods and compositions for treating ASDs in a
subject, as well as methods for screening for an ASD in a subject suspected of
having an ASD.
[0008] One aspect of the application is directed to a
method of treating an ASD in a subject. In this method, a composition
comprising of one or more
flavonoids, alone or in combination with, a serotonin blocker, a histamine- 1
receptor antagonist, a histamine-3 receptor agonist, an antipsychotic agent, a
heavy metal chelator, a neurotensin blocker, olive kernel extract and a
physiologically acceptable carrier, is administered to a subject in need
thereof, wherein the composition modulates the leakage of brain blood vessels.
SUMMARY OF THE INVENTION
(ANTI-INFLAMMATORY
COMPOSITIONS FOR TREATING BRAIN INFLAMMATION )
The invention comprises compositions for human use
containing one or more of a flavonoid compound, a non-bovine heavily sulfated
proteoglycan, an unrefined olive kernel extract, a sulfated hexosamine, S-adenosylmethionine (“SAM”),
histamine-1 receptor antagonists, histamine-3 receptor agonists, antagonists of
the actions of CRH, folic acid, a straight chain polyunsaturated fatty acid, a
phospholipid, a polyamine, an interferon and glutiramer acetate,
together with appropriate excipients and carriers, said compositions having
improved absorption from the gastrointestinal tract, skin surface, and nasal
and pulmonary surfaces, and anti-inflammatory effects synergistic with each
other and synergistic with available conventional clinical treatment modalities.
It has been discovered that various combinations of a
sulfated proteoglycan, unrefined olive kernel extract, a flavone (a.k.a.
flavonoid compound), a sulfated D-hexoseamine, a phospholipid, a long chain
unsaturated fatty acid, a CRH antagonist, a histamine-1 receptor antagonist, a
histamine-3 receptor agonist, glutiramer acetate, an interferon, and a
polyamine have synergistic anti-inflammatory effects when used as a dietary
supplement, a topical product or an aerosol for nasal or pulmonary administration,
without or with a conventional clinical treatment for inflammatory diseases.
Within the present context, such inflammatory diseases result from the
activation, degranulation and consequent secretion of inflammatory biochemicals
from mast cells, and the resultant inflammatory diseases include the group
consisting of: allergic inflammation, arthritis (to include osteoarthritis and
rheumatoid arthritis), fibromyalgia, chronic fatigue syndrome, inflammatory
bowel disease, interstitial cystitis, irritable bowel syndrome, migraines,
atherosclerosis, coronary inflammation, ischemia, chronic prostatitis, eczema,
multiple sclerosis, psoriasis, sun burn, periodontal disease of the gums,
superficial vasodilator flush syndromes, hormonally-dependent cancers, and
endometriosis. The olive kernel extract alone may be used to improve the
transmembrane transport of difficultly-absorbable biomolecules in the
intestine, skin and pulmonary alveoli.
The patent
goes into great detail of exactly which drugs might be included, and in the
second patent even the dosages.
Histamine H1 and H3 Agonists
I wrote
extensively in this blog about histamine and autism. Theoharides proposes to use an H1 agonist and
an H3 agonist. The problem is that H3
agonists are still experimental and unlicensed; however his choice of possible
H1 agonists is very interesting and something that can be applied today.
Azatadine is
an antihistamine and serotonin blocker
Azelastine
is a second generation antihistamine and mast cell stabilizer available as nose
spray or eye drops. Seems to be the most
effective for hay fever. OTC in UK
Cyproheptadine
or Periactin is a first generation antihistamine with additional anticholinergic,
antiserotonergic,
and local anesthetic properties. OTC in UK
A clinical trial exists in autism of this drug.
Hydroxyzine
another first generation antihistamine. Due to its antagonistic effects on
several receptor systems in the brain, hydroxyzine is
claimed to have strong anti-anxiety and mild antiobsessive as well as antipsychotic
properties
Merelastine
is another first generation antihistamine
Rupatadine is a second generation antihistamine
and PAF antagonist used to treat
allergies. It has mast cell stabilizing
properties.
Antipsychotic and Chelator
I was
surprised to see these drugs mentioned, the heavy metal chelator is meso-2,3-dimercaptosuccinic acid
(DMSA) and the
antipsychotic agent is risperidone.
The evidence for chelation actually looks a bit shaky. In fact two antioxidants proposed for use in
autism, NAC (N-acetyl cysteine) and ALA
(lipoic acid) are highly likely to remove any heavy metal nasties anyway.
Mitigating Methyl mercury Exposure: Study Confirms Potential of NAC as Antidote and Biomarker
I will be sticking with NAC and certainly not using antipsychotics, since they are known to have major side effects.
Neurotensin blocker
Neurotensin blocker
Neurotensin
(NT) is another neurotransmitter. Neurotensin has been implicated in the modulation of dopamine
signaling, and produces a spectrum of pharmacological effects resembling those
of antipsychotic drugs, leading to the suggestion
that neurotensin may be an endogenous neuroleptic.
Children with autism have elevated levels of NT and the level seems to
correlate with the severity of their autism.
Serotonin blocker
The serotonin blocker is azatadine or cyproheptadine. Both of these are actually H1 histamine
antagonists. Cyproheptadine, also known
as Periactin is
available OTC in some countries, including the UK.
SAMe, folic acid
Supplementation of the compositions
described above with the methylation reagent S-adenosylmethionine (“SAM”) adds
antioxidant, anti-inflammatory and cytoprotective properties, particularly in
inflammatory joint and cardiovascular diseases. Addition of SAM also
accelerates metabolism of homocysteine, which amino acid has been implicated in
coronary disease, to cysteine, which is harmless. Folic acid may be added to
certain of the present formulations for similar reasons.
In fact NAC
+ B12 is an alternative way to reduce homocysteine levels, as already mentioned
in an earlier post.
The Peter Polypill
I found Dr
Theoharides patents very interesting and it is encouraging to see that someone
is actually doing to some research, reading other peoples research and trying
to bring products to the market.
Of Theoharides’
ingredients, the ones I would also include in the Peter Polypill are the H1
agonists (including the serotonin blocker).
The
Neurotensin blocker and H3 agonist look interesting, but it will be many years
before they are licensed as drugs.
The hypothetical Peter Polypill is currently as follows:-
A twice daily effervescent tablet containing:-
Atorvastatin, with co-enzyme Q10 added to
counter the secondary effect of the statin
Bumetanide, with Ca, K, and Mg added to
counter the losses due to diuresis
NAC plus a small amount of acetyl-L carnitine
Rupatadine, as H1 agonist and mast cell
stabilizer
Taltirelin hydrate, the TRH analog
Vitamins D, B6, B9 and B12 + selenium
Then I would
give Dr Theoharides oil-based flavonoid supplement to help stabilize mast cells
and maybe, before bed I would add Periactin, the sedating H1 anti histamine and
serotonin blocker. For summertime allergies, it looks like the nasal spray containing Azelastine should be the best.
Ideally, we shall chase after:
ReplyDeleteRescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486 ….. Bridget M. Dolana, …. Susumu Tonegawa
Finally, a single administration of FRAX486 is sufficient to rescue all of these phenotypes in adult Fmr1 KO mice, demonstrating the potential for rapid, postdiagnostic therapy in adults with FXS.